The quarter also saw continued investment in new technologies and the successful implementation of several digitization and automation projects across operations
Emkay Research expects Q2FY22 to be a normalised quarter for pharma companies that it tracks. A summary of the report
_256_384.jpg)
CLSA, a capital market and investment group organised an Investors’ Forum where five Indian pharma companies participated. Excerpts from the report
Ind-Ra expects IPM revenue to grow over 12% YoY in FY22
_256_384.jpeg)
The company aims to continue its expansion via organic and inorganic routes to increase production capacity and product portfolio
Domestic business was up 41.9% YoY and 27.7% QoQ
The company reports revenue growth of 26% and PAT growth of 21% YoY
Demand normalisation post the second wave contributed to the steady growth
The profits were bolstered by the Boehringer Ingelheim MEK program income
This robust performance is a testimony of the company's agility, resilience and strong execution capabilities during these difficult times
Subscribe To Our Newsletter & Stay Updated
